Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Salarius Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing potential new cancer medicines for patients in need of new treatment options. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader. Salarius Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing potential new cancer medicines for patients in need of new treatment options. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
Decoy’s proprietary IMP3ACT™ peptide conjugate drug design and manufacturing platform leverages machine learning (ML) and artificial intelligence (AI) tools Decoy is leveraging non-dilutive...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.53 | -19.4139194139 | 2.73 | 2.9 | 2.14 | 69619 | 2.42004599 | CS |
| 4 | 0.51 | 30.1775147929 | 1.69 | 7.2 | 1.55 | 7429314 | 3.61698723 | CS |
| 12 | 0.74 | 50.6849315068 | 1.46 | 7.2 | 1.22 | 2339604 | 3.57933762 | CS |
| 26 | -0.91 | -29.2604501608 | 3.11 | 7.2 | 1.22 | 1366939 | 3.18251949 | CS |
| 52 | -1.96 | -47.1153846154 | 4.16 | 7.2 | 1.22 | 1238719 | 3.06227225 | CS |
| 156 | -89.8 | -97.6086956522 | 92 | 107.66 | 1.22 | 615919 | 16.34880361 | CS |
| 260 | -511.8 | -99.5719844358 | 514 | 700 | 1.22 | 781753 | 153.60518535 | CS |
| Symbol | Preis | Vol. |
|---|---|---|
| TCTMTCTM Kids IT Education Inc | US$ 0,764 (321,87%) | 731,1M |
| NVDANVIDIA Corporation | US$ 120,07 (-3,67%) | 388,5M |
| RIMEAlgorhythm Holdings Inc | US$ 0,02565 (5,12%) | 341,8M |
| CLEUChina Liberal Education Holdings Ltd | US$ 0,1938 (30,77%) | 237,15M |
| BHATBlue Hat Interactive Entertainment Technology | US$ 0,0355 (-11,25%) | 236,44M |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
